Piper Sandler Lifts Korro Bio to Overweight After Presentation on KRRO-121 for UCD and HE
Piper Sandler moved Korro Bio Inc. (NASDAQ: KRRO) from Neutral to Overweight and raised its price target to $30 from $11 after the company's Virtual Analyst Day. The upgrade centers on KRRO-121, a GalNAc-conjugated antisense oligonucleotide intended to address Urea Cycle Disorders and Hepatic Encephalopathy by lowering hyperammonemia through engine…